Janux Therapeutics To Host Virtual Event On Monday, December 2, 2024, At 4:30 PM ET Discussing Updated Clinical Data In Phase 1a Dose Escalation For JANX007 In MCRPC And Doses Selected For Phase 1b Expansion Studies
Janux Therapeutics To Host Virtual Event On Monday, December 2, 2024, At 4:30 PM ET Discussing Updated Clinical Data In Phase 1a Dose Escalation For JANX007 In MCRPC And Doses Selected For Phase 1b Expansion Studies
The virtual event will take place on Monday, December 2, 2024, at 4:30 PM ET
虚拟活动将在2024年12月2日星期一东部时间下午4:30举行
Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced it will host a virtual event on Monday, December 2, 2024, at 4:30 PM ET.
Janux Therapeutics, Inc. (纳斯达克:JANX) (Janux)是一家临床阶段的生物制药公司，通过应用其专有科技于肿瘤激活T细胞连接器（TRACTr）和肿瘤激活免疫调节器（TRACIr）平台，开发了一系列新型免疫疗法。今天宣布，它将在2024年12月2日星期一东部时间下午4:30举办一次虚拟活动。
David Campbell, Ph.D., President & Chief Executive Officer, will provide an update on JANX007 Phase 1a dose escalation data and doses selected for Phase 1b expansion studies in adult subjects with metastatic castration-resistant prostate cancer (mCRPC).
大卫·坎贝尔博士，总裁兼首席执行官，将提供关于JANX007第一阶段剂量递增数据和为患有转移性去势抵抗前列腺癌（mCRPC）成年受试者选择的10亿扩展研究剂量的最新信息。
译文内容由第三方软件翻译。
